4
Changes in Ownership
Vaxcyte, Inc. Filed Acc 0001649094-24-000071
PRESIDENT AND CFO sold 8,000 shares at an average $115.94 ($927,551)
- PRESIDENT AND CFO acquired 8,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| GUGGENHIME ANDREW PRESIDENT AND CFO | 2024-09-18 | Option exercise 10b5-1 | +8,000 | $5.35 | $42,800 | 98,383 | D |
| GUGGENHIME ANDREW PRESIDENT AND CFO | 2024-09-18 | Sale 10b5-1 | −5,485 | $115.60 | $634,052 | 92,898 | D |
| GUGGENHIME ANDREW PRESIDENT AND CFO | 2024-09-18 | Sale 10b5-1 | −1,686 | $116.29 | $196,065 | 91,212 | D |
| GUGGENHIME ANDREW PRESIDENT AND CFO | 2024-09-18 | Sale 10b5-1 | −829 | $117.53 | $97,433 | 90,383 | D |
| Derivatives | |||||||
| GUGGENHIME ANDREW PRESIDENT AND CFO | 2024-09-18 | Option exercise · Stock Option (right to buy) 10b5-1 | −8,000 | 320,827 | D | ||
| Open-market sales · 8,000 sh · avg $115.94 · $927,551 | |||||||
Loading xslF345X05/wk-form4_1726782498.xml…